Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP).
HPV vaccine
Intralesional injection of Bevacizumab
Recurrent respiratory papillomatosis
Surgery
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
29
02
2024
accepted:
30
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
Recent approaches for recurrent respiratory papillomatosis including local injection of bevacizumab and HPV vaccination show promise in reducing the need for frequent surgeries. In this study we propose a new combined approach of surgery, intralesional injection of 25 mg bevacizumab and HPV vaccine that can lead to resolution of RRP. Our study involved 5 patients treated with a combination of transoral microsurgery, intralesional injection of 25 mg bevacizumab, and HPV vaccination with Gardasil 9 between April 2020 and May 2023. Standard video laryngoscopy was performed to assess the presence of papilloma and Derkay score was used to assess the severity of disease. All 5 patients completed the study successfully and a complete response was achieved by all. The follow-up ranged from 8 to 45 months. The mean total Derkay score before treatment was 41 (range 25 to 52) and after the combined approach was 0 both anatomically and clinically in all patients. This study demonstrates the effectiveness of a combined treatment approach for RRP involving surgical intervention, intralesional injection of bevacizumab, and HPV vaccination.
Identifiants
pubmed: 38637412
doi: 10.1007/s00405-024-08653-6
pii: 10.1007/s00405-024-08653-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Dikkers FG, Seedat RY, San Giorgi MR (2022) Recurrent respiratory papillomatosis. In: Remacle M, Eckel HE (eds) Textbook of surgery of larynx and trachea. Springer, Cham
Manley C, Hutchinson C, Mahajan A, Ibrahim O, Folch E, Kumar R (2021) Treatment of recurrent respiratory papillomatosis: case series and review of technique. Surg Technol Int. 38:139–143. https://doi.org/10.52198/21.STI.38.GS1408
doi: 10.52198/21.STI.38.GS1408
pubmed: 33844241
Penaloza-Plascencia M, Montoya-Fuentes H, Flores-Martínez SE, Fierro-Velasco FJ, Peñaloza-González JM, Sánchez-Corona J (2000) Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 126(9):1119–1123. https://doi.org/10.1001/archotol.126.9.1119
doi: 10.1001/archotol.126.9.1119
pubmed: 10979126
Hoesli RC, Wingo ML, Richardson BE, Bastian RW (2020) Identification of 11 different HPV subtypes in adult patients with recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 163(4):785–790. https://doi.org/10.1177/0194599820931817
doi: 10.1177/0194599820931817
pubmed: 32571159
Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, Souza CA, Marchiori E (2017) Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med 126:116–121. https://doi.org/10.1016/j.rmed.2017.03.030
doi: 10.1016/j.rmed.2017.03.030
pubmed: 28427542
Larson DA, Derkay CS (2010) Epidemiology of recurrent respiratory papillomatosis. APMIS 118(6–7):450–454. https://doi.org/10.1111/j.1600-0463.2010.02619.x
doi: 10.1111/j.1600-0463.2010.02619.x
pubmed: 20553527
San Giorgi MR, Van Den Heuvel ER, TjonPianGi RE, Brunings JW, Chirila M, Friedrich G, Golusinski W, Graupp M, HorcasitasPous RA, Ilmarinen T, Jackowska J, Koelmel JC, FerranVilà F, Weichbold V, Wierzbicka M, Dikkers FG (2016) Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol. 41(5):448–453. https://doi.org/10.1111/coa.12565
doi: 10.1111/coa.12565
pubmed: 26460806
Gerein V, Schmandt S, Babkina N, Barysik N, Coerdt W, Pfister H (2007) Human papilloma virus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation. Cancer Detect Prev 31(4):276–281. https://doi.org/10.1016/j.cdp.2007.07.004
doi: 10.1016/j.cdp.2007.07.004
pubmed: 17935912
Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, Van Zandt S, Whitt S, Shah K (1992) A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102(1):9–13. https://doi.org/10.1288/00005537-199201000-00002
doi: 10.1288/00005537-199201000-00002
pubmed: 1309932
Padayachee A, Prescott CA (1993) Relationship between the clinical course and HPV typing of recurrent laryngeal papillomatosis. The Red Cross War Memorial Children’s Hospital experience 1982–1988. Int J Pediatr Otorhinolaryngol. 26(2):141–147. https://doi.org/10.1016/0165-5876(93)90019-y
doi: 10.1016/0165-5876(93)90019-y
pubmed: 8383099
Somers GR, Tabrizi SN, Borg AJ, Garland SM, Chow CW (1997) Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Pathol Lab Med 17(1):53–64
doi: 10.1080/15513819709168346
pubmed: 9050060
Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L (2004) Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114(11 Pt 2 Suppl 104):1–23. https://doi.org/10.1097/01.mlg.000148224.83491.0f
doi: 10.1097/01.mlg.000148224.83491.0f
pubmed: 15514560
Soldatski IL, Onufrieva EK, Steklov AM, Schepin NV (2005) Tracheal, bronchial, and pulmonary papillomatosis in children. Laryngoscope 115(10):1848–1854. https://doi.org/10.1097/01.mlg.0000173155.57491.2a
doi: 10.1097/01.mlg.0000173155.57491.2a
pubmed: 16222208
So RJ, McClellan K, Best SR (2023) Recurrent respiratory papillomatosis: quality of life data from an international patient registry. Laryngoscope 133(8):1919–1926. https://doi.org/10.1002/lary.30401
doi: 10.1002/lary.30401
pubmed: 36177852
Feyh J, Kastenbauer E (1992) Die Behandlung der Larynxpapillomatose mit Hilfe der photodynamischen Lasertherapie. Treatment of laryngeal papillomatosis with photodynamic laser therapy. Laryngorhinootologie 71(4):190–192. https://doi.org/10.1055/s-2007-997275
doi: 10.1055/s-2007-997275
pubmed: 1533523
Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL (1998) Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 118(6):810–815. https://doi.org/10.1016/S0194-5998(98)70274-8
doi: 10.1016/S0194-5998(98)70274-8
pubmed: 9627242
Fernández-Fernández H, Blanco-López Y, Viada-González C, López-Saura P, Cuban Group for the Study of Interferon in Recurrent Respiratory Papillomatosis (2004) Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report). J Laryngol Otol 118(9):681–687. https://doi.org/10.1258/0022215042244741
doi: 10.1258/0022215042244741
pubmed: 15517700
Pudszuhn A, Welzel C, Bloching M, Neumann K (2007) Intralesional Cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Oto Rhino Laryngol. 264(1):63–70. https://doi.org/10.1007/s00405-006-0151-6
doi: 10.1007/s00405-006-0151-6
Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE (2009) Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol 201:1–13. https://doi.org/10.1177/000348940911800901
doi: 10.1177/000348940911800901
Makiyama K, Hirai R, Matsuzaki H (2017) Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer. J Voice 31(1):104–106. https://doi.org/10.1016/j.jvoice.2016.01.008
doi: 10.1016/j.jvoice.2016.01.008
pubmed: 27068425
Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD (1998) A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope 108(6):935–937. https://doi.org/10.1097/00005537-199806000-00026
doi: 10.1097/00005537-199806000-00026
pubmed: 9628513
Collette F, Lawson G, Hassid S, Delahaut G, Bachy V, Van Der Vorst S, Faugeras L, Gilliaux Q, D’Hondt L (2023) Aggressive recurrent respiratory papillomatosis: a series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience. Head Neck. 45(5):1071–1079. https://doi.org/10.1002/hed.27300
doi: 10.1002/hed.27300
pubmed: 36840929
Maturo S, Hartnick CJ (2010) Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience. Arch Otolaryngol Head Neck Surg 136(6):561–565. https://doi.org/10.1001/archoto.2010.81
doi: 10.1001/archoto.2010.81
pubmed: 20566906
Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, Wiebe K, Müller KM, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE (2014) Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 8(5):1912–1918. https://doi.org/10.3892/ol.2014.2486
doi: 10.3892/ol.2014.2486
pubmed: 25289079
pmcid: 4186578
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https://doi.org/10.1016/j.ctrv.2020.102017
doi: 10.1016/j.ctrv.2020.102017
pubmed: 32335505
Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, Brown LF (2005) Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 114(4):289–295. https://doi.org/10.1177/000348940511400407
doi: 10.1177/000348940511400407
pubmed: 15895784
Best SR, Friedman AD, Landau-Zemer T, Barbu AM, Burns JA, Freeman MW, Halvorsen YD, Hillman RE, Zeitels SM (2012) Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 121(9):587–593. https://doi.org/10.1177/000348941212100905
doi: 10.1177/000348941212100905
pubmed: 23012897
Rogers DJ, Ojha S, Maurer R, Hartnick CJ (2013) Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg. 139(5):496–501. https://doi.org/10.1001/jamaoto.2013.1810
doi: 10.1001/jamaoto.2013.1810
pubmed: 23681032
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (London, England) 364(9447):1757–1765. https://doi.org/10.1016/S0140-6736(04)17398-4
doi: 10.1016/S0140-6736(04)17398-4
pubmed: 15541448
Bowyer HL, Marlow LA, Hibbitts S, Pollock KG, Waller J (2013) Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine 31(7):1051–1056. https://doi.org/10.1016/j.vaccine.2012.12.038
doi: 10.1016/j.vaccine.2012.12.038
pubmed: 23277094
Garland SM, Kjaer SK, Muñoz N et al (2016) Impact and effectiveness of the quadrivalent Human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. https://doi.org/10.1093/cid/ciw354
doi: 10.1093/cid/ciw354
pubmed: 28011607
pmcid: 4967609
Baumanis MM, Elmaraghy CA (2016) Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: a case report. Int J Pediatr Otorhinolaryngol 91:166–169. https://doi.org/10.1016/j.ijporl.2016.10.032
doi: 10.1016/j.ijporl.2016.10.032
pubmed: 27863633
Fancello V, Melis A, Piana AF, Castiglia P, Cossu A, Sotgiu G, Bozzo C, King EV, Meloni F (2015) HPV type 6 and 18 coinfection in a case of adult-onset laryngeal papillomatosis: immunization with gardasil. Case Rep Otolaryngol 2015:916023. https://doi.org/10.1155/2015/916023
doi: 10.1155/2015/916023
pubmed: 26783482
pmcid: 4691470
Ponduri A, Azmy MC, Axler E, Lin J, Schwartz R, Chirilă M, Dikkers FG, Yang CJ, Mehta V, Gangar M (2023) The efficacy of human papillomavirus vaccination as an adjuvant therapy in recurrent respiratory papillomatosis. Laryngoscope 133(9):2046–2054. https://doi.org/10.1002/lary.30560
doi: 10.1002/lary.30560
pubmed: 36651338
Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig AK, Wehberg S, Chirilǎ M, Godballe C (2019) Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis 219(7):1016–1025. https://doi.org/10.1093/infdis/jiy616
doi: 10.1093/infdis/jiy616
pubmed: 30358875